<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626908</url>
  </required_header>
  <id_info>
    <org_study_id>GC022F-ZhejiangU</org_study_id>
    <nct_id>NCT04626908</nct_id>
  </id_info>
  <brief_title>Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>He Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the&#xD;
      Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, single-center, open clinical study to evaluate the safety and efficacy&#xD;
      of GC022F injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Within 28 days after cell infusion</time_frame>
    <description>Proportion of patients with dose limiting toxicity (DLT) after cell infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>24 months after cell infusion</time_frame>
    <description>Incidence of treatment-emergent adverse events [Safety and Tolerability]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate(ORR)</measure>
    <time_frame>Month 1,3,6,12,18and 24</time_frame>
    <description>Assessment of ORR (ORR = CR + CRi ) at Month 1,3,6,12,18and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Month 6,12,18and 24</time_frame>
    <description>Assessment of PFS at Month 6,12,18and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Month 6,12,18and 24</time_frame>
    <description>Assessment of OS at Month 6,12,18and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>Month 6,12,18and 24</time_frame>
    <description>Assessment of OS at Month 6,12,18and 24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Relapsed and Refractory</condition>
  <condition>Lymphoid Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Administration of GC022F CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receive GC022F CAR T-cells by intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC022F CAR-T cells</intervention_name>
    <description>Each subject receive GC022F CAR-T cells by intravenous infusion</description>
    <arm_group_label>Administration of GC022F CAR-T cells</arm_group_label>
    <other_name>GC022F CAR-T cells injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18-75 years old (including the threshold value);&#xD;
&#xD;
          2. Histologically confirmed as diffuse large B-cell lymphoma (DLBCL), transformed&#xD;
             follicular lymphoma (TFL), or primary mediastinal B-cell lymphoma (PMBCL) :&#xD;
&#xD;
             i. Refractory B-NHL: PD was the optimal response to standard first-line treatment&#xD;
             (those with intolerance to first-line treatment were not included in this study); Or&#xD;
             SD after at least 4 courses of first-line treatment, and the DURATION of SD shall not&#xD;
             exceed 6 months after the last treatment; Or the subjects' best response to the last&#xD;
             treatment of second-line or above treatment is PD, or SD after at least 2 courses of&#xD;
             second-line or above treatment, and the SD maintenance time is not more than 6 months;&#xD;
             Or:&#xD;
&#xD;
             ii. Relapsed B-NHL: after standard systemic treatment and complete remission after&#xD;
             second-line treatment, the disease recurred as certified by histopathology, or the&#xD;
             recurrence as confirmed by histopathology within 1 year after autologous hematopoietic&#xD;
             stem cell transplantation (not limited by previous treatment methods);&#xD;
&#xD;
             iii. Patients with INVERt follicular lymphoma must receive chemotherapy prior to&#xD;
             transformation and meet the above definition of recurrent or refractory after&#xD;
             transformation;&#xD;
&#xD;
          3. according to Lugano treatment response standard (2014 version), there should be at&#xD;
             least one evaluable tumor lesion: the longest diameter of the injunctional lesion was&#xD;
             &gt; 1.5cm, and the longest diameter of the injunctional lesion was b&gt; 1.0cm;&#xD;
&#xD;
          4. Positive expression of CD19 and CD22 in biopsy sections of tumor tissues;&#xD;
&#xD;
          5. Patients who have failed or relapsed after single-target CAR-T therapy may also be&#xD;
             enrolled.&#xD;
&#xD;
          6. Prior to the study, the approved anti-B-NHL treatment, such as systemic chemotherapy,&#xD;
             general radiotherapy and immunotherapy, has been completed for at least 2 weeks;&#xD;
&#xD;
          7. ECOG≤1；&#xD;
&#xD;
          8. Expected survival ≥3 months;&#xD;
&#xD;
          9. Absolute count of neutrophils ≥ 1×109/L;&#xD;
&#xD;
         10. Platelet count ≥50×109/L;&#xD;
&#xD;
         11. Absolute lymphocyte count ≥1×108/L;&#xD;
&#xD;
         12. Adequate organ function reserve:&#xD;
&#xD;
               1. ALANINE aminotransferase and aspartate aminotransferase ≤ 2.5× UNL (upper limit&#xD;
                  of normal value);&#xD;
&#xD;
               2. Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min;&#xD;
&#xD;
               3. Serum total bilirubin ≤1.5× UNL;&#xD;
&#xD;
               4. The left ventricular ejection fraction (LVEF) of the subject was diagnosed by&#xD;
                  echocardiography ≥50%, and no clinically significant pericardial effusion was&#xD;
                  observed, and no clinically significant ecg abnormalities were observed;&#xD;
&#xD;
               5. under natural indoor air environment, the basic oxygen saturation of &gt; is 92%;&#xD;
&#xD;
         13. Vein access required for collection can be established, and there are no&#xD;
             contraindications for leukocyte collection;&#xD;
&#xD;
         14. Women of childbearing age had negative pregnancy test during screening period and&#xD;
             before administration, and agreed to take effective contraceptive measures at least&#xD;
             one year after infusion; male subjects with fertile partners must agree to use&#xD;
             effective barrier contraceptive method at least one year after infusion and avoid&#xD;
             sperm donation;&#xD;
&#xD;
         15. Voluntary signing of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other tumors (except cured non melanoma skin cancer, cervical cancer in situ,&#xD;
             superficial bladder cancer, breast ductal carcinoma in situ, or other malignant tumors&#xD;
             with complete remission for more than 5 years);&#xD;
&#xD;
          2. Persons with severe mental disorders;&#xD;
&#xD;
          3. A history of hereditary diseases such as Fanconi anemia, Schrader syndrome, Costerman&#xD;
             syndrome, or any other known bone marrow failure syndrome;&#xD;
&#xD;
          4. A history of allogeneic stem cell transplantation;&#xD;
&#xD;
          5. Heart disease with grade III-IV heart failure [New York Heart Association (NYHA)&#xD;
             classification] or myocardial infarction, cardiac angioplasty or stenting, unstable&#xD;
             angina pectoris, or other clinically significant cardiac conditions within the year&#xD;
             prior to enrollment;&#xD;
&#xD;
          6. The presence of any indwelling catheter or drainage tube (e.g., percutaneous&#xD;
             nephrostomy tube, bile drainage tube or pleural/peritoneal/pericardial catheter),&#xD;
             allowing the use of a dedicated central venous catheter;&#xD;
&#xD;
          7. Subjects with a history of CNS lymphoma, cerebrospinal fluid malignant cells or brain&#xD;
             metastasis;&#xD;
&#xD;
          8. A history or disease of the central nervous system, such as seizure disorder, cerebral&#xD;
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving&#xD;
             CNS;&#xD;
&#xD;
          9. The results of any of the following virology-ELISA tests were positive: HIV antibody,&#xD;
             HCV antibody, TPPA, hepatitis B surface antigen;&#xD;
&#xD;
         10. There were active infections requiring systematic treatment within 2 weeks before&#xD;
             single collection;&#xD;
&#xD;
         11. Persons with a known severe allergic reaction to cyclophosphamide or fludarabine, or&#xD;
             with an allergic constitution;&#xD;
&#xD;
         12. A history of an autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis,&#xD;
             systemic lupus erythematosus) that has caused injury to the terminal organs or&#xD;
             requires systemic immunosuppressive/disease-modulating drugs within the past 2 years;&#xD;
&#xD;
         13. Pulmonary fibrosis is present;&#xD;
&#xD;
         14. Has received treatment in another clinical trial within 4 weeks prior to participation&#xD;
             in this trial, or the date of signing of the informed consent is within 5 half-lives&#xD;
             (whichever is longer) of the last medication used in the last other clinical trial;&#xD;
&#xD;
         15. Poor compliance due to physiological, family, social, geographical and other factors,&#xD;
             unable to comply with the research program and follow-up plan;&#xD;
&#xD;
         16. The presence of a comorbiditie requiring systemic corticosteroid therapy (≥5 mg/ day&#xD;
             of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive&#xD;
             agents within 6 months of study treatment was determined by the investigator;&#xD;
&#xD;
         17. Lactating women who do not want to stop breastfeeding;&#xD;
&#xD;
         18. Any other condition that the researcher considers inappropriate to be included in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>He Huang, MD</last_name>
    <phone>86-13605714822</phone>
    <email>hehuangyu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongxian Hu, MD</last_name>
    <phone>86-15957162012</phone>
    <email>huyongxian2000@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of medical college of zhejiang university</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>He Huang, MD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 7, 2020</last_update_submitted>
  <last_update_submitted_qc>November 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>lymphoid hematological malignancies</keyword>
  <keyword>CAR-T cell therapy</keyword>
  <keyword>CD19</keyword>
  <keyword>CD22</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

